{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-003413","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2024-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.509521+00:00","generated_at":"2026-06-06T23:59:48.409194+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Onconetix CEO Neil Campbell resigns; interim CEO and Lead Independent Director appointed","bullets":["Dr. Neil Campbell resigned as President, CEO, and board member effective Jan 10, 2024; no disagreement cited.","Campbell receives $158,333 severance payment under a release of claims filed as Exhibit 99.1.","Dr. Ralph Schiess, Chief Science Officer, appointed Interim CEO effective Jan 12, 2024.","James Sapirstein named Lead Independent Director; will receive $40,000 per month for that role."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-003413","json":"https://secwatch.observer/filing/0001213900-24-003413.json","markdown":"https://secwatch.observer/filing/0001213900-24-003413.md","text":"https://secwatch.observer/filing/0001213900-24-003413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/ea191591-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:59:48.409194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"326b80a204","claim":"Dr. Neil Campbell resigned as President and Chief Executive Officer at Onconetix, Inc..","evidence_excerpt":"Effective as of January 10, 2024, Dr. Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"44412208c3","claim":"James Sapirstein was appointed as Lead Independent Director at Onconetix, Inc..","evidence_excerpt":"Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board’s appointment of a permanent chief executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"},{"claim_id":"b80e0e56d2","claim":"Dr. Ralph Schiess was appointed as Interim Chief Executive Officer at Onconetix, Inc..","evidence_excerpt":"On January 12, 2024, the Board appointed Dr. Ralph Schiess, the Company’s Chief Science Officer, to serve as the Company’s Interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}